Wedbush Analysts Give Ascendis Pharma A/S (NASDAQ:ASND) a $219.00 Price Target

Ascendis Pharma A/S (NASDAQ:ASND) has been assigned a $219.00 target price by equities researchers at Wedbush in a research report issued on Monday, May 20th, TipRanks reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Wedbush’s target price would indicate a potential upside of 81.16% from the company’s previous close.

A number of other equities research analysts also recently issued reports on ASND. Zacks Investment Research downgraded shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 18th. Cantor Fitzgerald reiterated a “buy” rating and set a $185.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, March 18th. BidaskClub upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Friday, May 10th. Evercore ISI started coverage on shares of Ascendis Pharma A/S in a research note on Monday, March 25th. They set an “outperform” rating on the stock. Finally, Canaccord Genuity increased their price objective on shares of Ascendis Pharma A/S from $132.00 to $133.00 and gave the stock a “buy” rating in a research note on Friday, April 5th. One equities research analyst has rated the stock with a sell rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $137.22.

Shares of ASND traded down $1.48 during trading hours on Monday, hitting $120.89. The company had a trading volume of 252,429 shares, compared to its average volume of 346,671. The firm has a market capitalization of $5.07 billion, a PE ratio of -32.32 and a beta of 0.78. Ascendis Pharma A/S has a 12 month low of $53.21 and a 12 month high of $133.96. The company has a debt-to-equity ratio of 0.02, a current ratio of 22.32 and a quick ratio of 22.32.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.30. Ascendis Pharma A/S had a negative net margin of 901.89% and a negative return on equity of 34.64%. The business had revenue of $12.00 million for the quarter. Analysts predict that Ascendis Pharma A/S will post -5.42 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Artisan Partners Limited Partnership boosted its position in Ascendis Pharma A/S by 208.2% during the 1st quarter. Artisan Partners Limited Partnership now owns 1,131,107 shares of the biotechnology company’s stock worth $133,131,000 after buying an additional 764,160 shares during the period. FMR LLC boosted its position in Ascendis Pharma A/S by 11.6% during the 1st quarter. FMR LLC now owns 4,692,707 shares of the biotechnology company’s stock worth $552,332,000 after buying an additional 489,461 shares during the period. Marshall Wace North America L.P. boosted its position in Ascendis Pharma A/S by 56.4% during the 1st quarter. Marshall Wace North America L.P. now owns 1,161,476 shares of the biotechnology company’s stock worth $136,706,000 after buying an additional 418,717 shares during the period. Victory Capital Management Inc. boosted its position in Ascendis Pharma A/S by 1,284.0% during the 1st quarter. Victory Capital Management Inc. now owns 322,718 shares of the biotechnology company’s stock worth $37,984,000 after buying an additional 299,400 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Ascendis Pharma A/S during the 1st quarter worth approximately $21,705,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

See Also: Street Name

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply